<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742000</url>
  </required_header>
  <id_info>
    <org_study_id>IAR-KT-POST</org_study_id>
    <nct_id>NCT01742000</nct_id>
  </id_info>
  <brief_title>Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women</brief_title>
  <acronym>PEARS-POST</acronym>
  <official_title>Double-blinded Placebo-controlled Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Atherosclerosis Research, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Atherosclerosis Research, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the anti-atherosclerotic action of natural drug
      Karinat based on phytoestrogen-rich botanicals in postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B-mode ultrasound of carotid arteries</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Variation of intima-media thickness of common carotid arteries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of serum atherogenicity</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Change of the ability of serum to induce cholesterol accumulation in cultured cells</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Karinat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Karinat 500 mg tablet by mouth three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500 mg tablet by mouth three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Karinat</intervention_name>
    <arm_group_label>Karinat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic Karinat 500 mg tablet</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at least 5 years after menopause

          -  Maximum intima-media thickness of common carotid artery more than 0,80 mm
             (ultrasonographic B-mode examination)

          -  The absence of climacteric syndrome (less than 3 points by Blatt-Kupperman scale)

          -  The absence of chronic diseases demanding permanent drug administration (more than 2
             month per year)

          -  The absence of hypolipidemic therapy or hormone replacement therapy during 6 months
             before the inclusion

        Exclusion Criteria:

          -  Administration of lipid-lowering drugs, and/or hormone replacement therapy, and/or
             phytoestrogens during 6 month before inclusion

          -  Continuous administration of sulfonylurea derivatives, and/or beta-blockers, and/or
             calcium antagonists (more than 2 months per year)

          -  Personal history or diagnostic of following diseases:

               1. Personal history of stroke, coronary heart disease, acute myocardial infarction
                  or transient ischemic attacks

               2. Pulmonary thromboembolism

               3. Chronic heart failure IIa-III

               4. Uncontrolled arterial hypertension (systolic blood pressure &gt; 145 mmHg, diastolic
                  blood pressure &gt; 95 mmHg under hypotensive therapy)

               5. Malignancy

               6. Chronic renal failure II-III

               7. Chronic hepatic failure II-III

               8. Liver cirrhosis

               9. Individual intolerance of Karinat or major side effects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2012</study_first_submitted>
  <study_first_submitted_qc>December 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmenopause</keyword>
  <keyword>phytoestrogen</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>intima-media thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Beta Carotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

